10x Genomics Launches 5,000-Plex Gene Panel for Xenium: A Quantum Leap in Gene Analysis’
Pleasanton, Calif. May 29, 2024 - In an era defined by the rapid advancement of biotechnology, 10x Genomics, Inc. (Nasdaq: TXG), a vanguard in single-cell and spatial biology, has once again forged ahead with the launch of its revolutionary Xenium Prime 5K Pan-Tissue and Pathways gene panel. This trailblazing development marks a significant stride forward, amplifying the capacity for gene analysis by an order of magnitude and setting a new benchmark for speed and throughput within the industry.
The Xenium Prime 5K panel boasts the ability to analyze 5,000 genes simultaneously, representing a tenfold increase in multiplexing capacity compared to existing solutions. This impressive enhancement does not merely quantify an uptick in capability but rather signifies a qualitative evolution that promises to unravel complex biological pathways with unprecedented granularity.
The introduction of the Xenium Prime 5K panel signifies not only a leap in technological prowess but also a profound shift in how we approach gene expression analysis, said Serge Saxonov, CEO and Co-Founder of 10x Genomics. Our goal has always been to equip researchers with tools that transcend the current limitations and unlock deeper insights into the cellular landscape.
What sets the Xenium Prime 5K apart is its industry-leading speed and throughput. In disciplines where time is often inextricably linked to the progression of research and, by extension, the onset of treatments, the ability to deliver faster and more comprehensive results can catalyze significant breakthroughs. Researchers can now process more samples in less time, thereby accelerating the journey from hypothesis to discovery.
Moreover, the panel is designed with a pan-tissue approach, making it universally applicable across a diverse array of research areas. Whether the focus is oncology, immunology, neurology, or any other field reliant on intricate gene expression patterns, Xenium Prime 5K stands as a versatile tool ready to meet the demands of contemporary science.
Our comprehensive approach ensures that no matter the tissue type or biological pathway under investigation, researchers have the tools they need for accurate and expansive analysis, noted Ben Hindson, Co-Founder and Chief Scientific Officer of 10x Genomics. This panel is a testament to our commitment to innovation and our drive to push the boundaries of what’s possible in gene analysis.
The introduction of this state-of-the-art gene panel aligns seamlessly with 10x Genomics’ overarching mission to advance biological understanding and improve human health. By enhancing the capabilities of spatial biology and single-cell analysis, the Xenium Prime 5K stands ready to facilitate new discoveries and support the growing demands of personalized medicine.
As the realms of genomics and biotechnology continue to evolve at breakneck speed, the introduction of the Xenium Prime 5K panel positions 10x Genomics at the helm of a transformative wave, propelling the industry towards a future where in-depth, rapid, and wide-ranging gene analysis becomes the norm rather than the exception.
As researchers and scientists around the globe pivot to leverage the enhanced capabilities of the Xenium Prime 5K, the ripple effects of this groundbreaking tool will undoubtedly resonate across myriad facets of biological research and clinical applications, heralding a new era in the quest to decode life’s most intricate mysteries.
With the Xenium Prime 5K, 10x Genomics continues to exemplify their dedication to pioneering scientific excellence and leading the charge towards the next frontier of gene analysis.
Comments